Dr. Hope S. Rugo
Medical Oncologist · Breast CancerDr. Hope S. Rugo, MD, is an internationally recognized breast medical oncologist and physician–scientist who holds the position of Senior Medical Director of Oncology and Hematology at City of Hope, one of the nation's leading cancer research and treatment centers. She also serves as Professor of Medicine at the City of Hope National Medical Center. Dr. Rugo received her medical degree from the University of Pennsylvania School of Medicine and completed her residency at UCSF, followed by fellowship training in hematology and oncology. She is triple board-certified in internal medicine, medical oncology, and hematology, offering comprehensive care to patients with breast cancer across all stages.
Dr. Rugo is renowned for her leadership in clinical trials and translational research aimed at improving treatment outcomes in breast cancer, particularly in metastatic disease and treatment-resistant tumors. She has led groundbreaking studies on novel targeted therapies, immune-based treatments, and supportive care strategies that have significantly influenced clinical practice. Her work has been instrumental in securing FDA approvals for several breakthrough treatments in breast oncology. Dr. Rugo has authored over 300 peer-reviewed publications and frequently contributes her expertise at major oncology forums around the world.
In addition to her research and clinical roles, Dr. Rugo is a dedicated mentor and educator committed to advancing the next generation of oncologists and scientists. She actively participates in numerous professional societies, including ASCO and ESMO, and sits on advisory panels that shape international cancer care guidelines. Through her visionary leadership, patient-centered philosophy, and commitment to innovation, Dr. Rugo continues to elevate standards in breast cancer treatment and research, making a lasting impact on the global oncology community.
Education
Medical School:
University of Pennsylvania School of Medicine
Residency:
Internal Medicine, University of California San Francisco
Fellowship:
Hematology and Oncology, University of California San Francisco
Board Certification:
Medical Oncology
Hematology
Internal Medicine
Awards
- European Society for Medical Oncology's 2024 Breast Cancer Award
- UCSF Clinical Cancer Center Investigator Research Program Intramural Award
- Breast Cancer Research Award - Friends of the Breast Care Center
- Bank of America Gianini Foundation Award
Memberships and affiliations
- American Society of Clinical Oncology
- Alliance for Clinical Trials in Oncology
- Translational Breast Cancer Research Consortium
- Investigator, I-SPY2 Trial
- Women's Cancers Program, City of Hope
- Division Chief, Breast Medical Oncology, City of Hope
- Professor, Department of Medical Oncology and Therapeutics Research, City of Hope
Research and publications
- Clinical validity of repeated circulating tumor cell enumeration as an early treatment monitoring tool for metastatic breast cancer in the PREDICT global pooled analysis.
- Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and antiemetogenic antibody-drug conjugates.
- Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials.
- Redefining Clinical Trial Strategic Design to Support Drug Approval in Medical Oncology.
- Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial.
- Health-related quality of life in patients with HR+/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the NATALEE trial.
- Dynamics of molecular heterogeneity in high-risk luminal breast cancer – from instrinsic to adaptive subtypes.
- Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care.
- Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).
- Developing alert thresholds and self-management advice for people receiving immune checkpoint inhibitors: a multinational association for supportive care in cancer modified Delphi surgery.
- Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting.
- Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials.
Other medical oncologist listed alphabetically, never by payment.
Browse all doctors →Open trials for these cancers, with the eligibility rules written in plain language.
Search trials →